Conditions & Recovery · ScienceDaily Cancer · July 26, 2026

CRISPR makes prostate cancer vulnerable to immunotherapy

Scientists used CRISPR to make prostate cancer cells easier for the immune system to detect and destroy. The experimental treatment dramatically improved the effects of immunotherapy in mice and may offer hope for other hard-to-treat tumors.

Originally published by ScienceDaily Cancer. We curate and add context; they did the reporting.

Read the full story at ScienceDaily Cancer ↗

Related learning

Biotech Firm Claims Some Credit for Groundbreaking Virus Research Biotech Firm Claims Some Credit for Groundbreaking Virus Research James P. Allison, Ph.D., bangs gong after completing proton therapy treatment Combination therapy helps plasmacytoid bladder cancer survivor